Treatment of herpes zoster with topical tetracaine
AssigneePagari Life Science Corp
InventorsAlan J. Wickenhauser, Stephen E. Peipert
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating herpes zoster (shingles), such as in the acute eruptive phase, or deactivating varicella zoster virus (the virus that causes herpes zoster), such as an in a patient suffering from herpes zoster, comprising topically administering tetracaine base (or a pharmaceutically acceptable salt thereof) to a patient in need of such treatment.
Claims18
A method of deactivating varicella zoster virus in a patient in need thereof, where the patient suffers from herpes zoster, comprising topically administering to the patient a composition comprising (a) from about 2 wt. % to about 10 wt. % of tetracaine base or a pharmaceutically acceptable salt thereof, (b) from about 2 to about 8 wt. % sodium carboxymethyl cellulose, (c) from about 2 to about 10 wt. % of polyethylene oxide, (d) from about 5 to about 15 wt. % propylene glycol, (e) from about 65 to about 85 wt. % plasticized base, and optionally (f) about 0.4 to about 1.0 wt. % peppermint oil and wherein the tetracaine base is the sole active ingredient in the composition.
A method of deactivating varicella zoster virus in a patient in need thereof comprising topically administering to the patient an effective amount of a composition comprising (a) from about 2 wt. % to about 10 wt. % of tetracaine base or a pharmaceutically acceptable salt thereof, (b) from about 2 to about 8 wt. % sodium carboxymethyl cellulose, (c) from about 2 to about 10 wt. % of polyethylene oxide, (d) from about 5 to about 15 wt. % propylene glycol, (e) from about 65 to about 85 wt. % plasticized base, and optionally (f) about 0.4 to about 1.0 wt. % peppermint oil and wherein the tetracaine base is the sole active ingredient in the composition.
A method of deactivating varicella zoster virus in a patient in need thereof, where the patient suffers from herpes zoster and is in the active eruptive phase of herpes zoster, comprising topically administering to the patient a composition comprising a) from about 2 wt. % to about 10 wt. % of tetracaine base or a pharmaceutically acceptable salt thereof, (b) from about 2 to about 8 wt. % sodium carboxymethyl cellulose, (c) from about 2 to about 10 wt. % of polyethylene oxide, (d) from about 5 to about 15 wt. % propylene glycol, (e) from about 65 to about 85 wt. % plasticized base, and optionally (f) about 0.4 to about 1.0 wt. % peppermint oil and wherein the tetracaine base is the sole active ingredient in the composition.
Dependencies are inferred from the claim text.